BRCA2 mutations have been identified in men with high-grade, aggressive prostate cancer [56], and ACA coverage of prostate cancer screening (see Table 1 and Table 2) has led to an observed 3% increase in screening among men, less than 138% of the FPL in early expansion states [57]. The gene discussed is BRCA2; the disease is Familial prostate cancer.